Market Activity - On July 11, the A-share market showed active trends with 61 stocks hitting the daily limit up, and a total of 17 stocks achieved consecutive limit ups, resulting in a success rate of 69% for limit orders [1] - The market focused on several strong stocks, with Sifang New Materials achieving a remarkable five consecutive limit ups, and Guotou Zhonglu also performing well with a T-shaped limit up, reaching five consecutive limit ups [1] - Stocks like Jingyi Co. and Yamaton achieved their fifth limit up within eight trading days through reverse limit up strategies [1] Stock Performance - Among the stocks with consecutive limit ups, Forest Packaging demonstrated a strong performance with seven consecutive limit ups, while companies like Shuangwei New Materials, Nanhua Futures, and Hemei Group achieved three consecutive limit ups [1] - ST Yazhen maintained an impressive performance with 12 limit ups over 15 days, while Yamaton and Jingyi Co. kept a pace of five limit ups over eight days [2] Market Sentiment and Capital Inflow - The market showed positive sentiment with active participation from investors, as evidenced by over 15 billion yuan in limit order funds supporting Shuangwei New Materials, and several other stocks like Sifang New Materials and Jin'an Guoji also receiving billions in limit order funds [1] - The total trading volume in the Shanghai and Shenzhen markets exceeded 1.7 trillion yuan, marking the highest level in nearly four months, indicating a significant increase in overall market activity and investor engagement [1] Sector Performance - The non-ferrous metal sector was notably active, with stocks like Hunan Silver and China Nonferrous Metals achieving limit ups [1] - The rare earth permanent magnet sector also showed strength, with companies like Northern Rare Earth and Jingyuntong achieving two consecutive limit ups, while Baogang Group and China Rare Earth also hit limit ups [1] - The securities IT sector attracted capital interest, with stocks like Jinzhen Co. and Guo'ao Technology hitting limit ups [1]

Group 1 - ST Unimed (002581) has been placed under other risk warnings due to its subsidiary Tianjin Unimed Biopharmaceutical Co., Ltd. being unable to resume normal operations within three months, leading to a stock suspension on July 7 and a subsequent name change to "ST Unimed" upon resumption [1] - The company's board acknowledges the negative impact of this situation and is taking effective measures to mitigate uncertainties, including cooperating with regulatory authorities for defect rectification and optimizing management to enhance profitability [1] - The company has completed a capital increase of 45 million yuan in its wholly-owned subsidiary Peking University Unimed (Shanghai) Biopharmaceutical Co., Ltd., acquiring a 51% stake in Sichuan Gukang Pharmaceutical Co., Ltd., which is expected to contribute revenue and profit starting from the 2025 semi-annual report [1] Group 2 - Sichuan Gukang Pharmaceutical, established in 2012, focuses on the procurement, processing, research, and sales of traditional Chinese medicine, offering over 400 high-quality products [2] - In 2024, Gukang Pharmaceutical reported revenues of 73.93 million yuan and a net profit of 4.15 million yuan, with a significant increase in performance expected in 2025, as revenues from January to April 2025 already surpassed the entire 2024 net profit [2] - The acquisition aims to enhance the pharmaceutical supply chain and explore opportunities in traditional Chinese medicine, leveraging Gukang's established market presence and customer resources to create synergies with existing business [2] Group 3 - The company is also making progress in its own operations, with a focus on strengthening its professional R&D platform, particularly through its subsidiary Shandong Yandu Biotechnology Co., Ltd. [3] - Shandong Yandu has developed a high-expression recombinant protein platform and is advancing multiple drug research systems, including a new ophthalmic drug that has completed Phase II clinical trials and is preparing for Phase III [3] - The core product, injectable mouse nerve growth factor, generated approximately 139 million yuan in revenue in 2024, while the new ophthalmic drug, a second-generation recombinant human nerve growth factor, has high clinical value and potential to become the first recombinant human nerve growth factor eye drop in China [3]

Core Viewpoint - Shandong Weiming Pharmaceutical Co., Ltd. faces significant operational challenges due to the suspension of production and sales at its subsidiary Tianjin Weiming Biopharmaceutical Co., Ltd., leading to a risk warning for its stock and a change in trading status to "ST Weiming" [1][3]. Group 1: Stock Trading and Risk Warnings - Tianjin Weiming was subjected to risk control measures on April 22, 2025, and is expected to be unable to resume normal operations within three months as of July 4, 2025, triggering a risk warning under the Shenzhen Stock Exchange regulations [1][3]. - The company's stock price experienced a cumulative decline of 15.82% over three consecutive trading days starting July 8, 2025, indicating abnormal trading fluctuations [1][2]. Group 2: Financial Impact and Company Performance - In 2024, Tianjin Weiming generated revenue of RMB 216.57 million and incurred a net loss of RMB 14.00 million, accounting for 60.09% of the company's total revenue and 9.8% of the consolidated net profit [2]. - For the fiscal year 2024, the company reported total revenue of RMB 360.41 million and a net loss attributable to shareholders of RMB 137.31 million, with the first quarter of 2025 showing revenue of RMB 35.33 million and a continued net loss [3].

山东未名生物医药股份有限公司（以下简称"公司"）控股子公司天津未名 生物医药有限公司（以下简称"天津未名"）于 2025 年 4 月 22 日被采取暂停生 产、销售风险控制措施。2025 年 7 月 4 日，因试验进度未及预期，天津未名预 计在三个月内无法恢复正常生产经营活动，上述情形触及《深圳证券交易所股票 上市规则》（2025 年修订）中公司被实施其他风险警示的有关规定，公司股票交 易被实施其他风险警示，自 2025 年 7 月 8 日开市起，证券简称由"未名医药" 变更为"ST 未名"，股票交易日涨跌幅限制 5%。 证券代码：002581 证券简称：未名医药 公告编号：2025-047 山东未名生物医药股份有限公司 关于股价异动及风险提示的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 一、股票交易异常波动的情况 山东未名生物医药股份有限公司（以下简称"公司"）股票交易价格于 2025 年 7 月 8 日、2025 年 7 月 9 日、2025 年 7 月 10 日连续三个交易日收盘价格跌幅 累计偏离-15.82%，根据深圳证券交 ...

ST未名（002581）公告，公司控股子公司天津未名生物医药有限公司因被采取暂停生产、销售风险控 制措施，且预计三个月内无法恢复正常生产经营活动，触及《深圳证券交易所股票上市规则》相关规 定，自2025年7月8日起被实施其他风险警示，股票简称变更为"ST未名"，股票交易日涨跌幅限制5%。 ...

Core Viewpoint - The suspension of production at Tianjin Weiming Biopharmaceutical Co., Ltd. has led to Shandong Weiming Pharmaceutical Co., Ltd. being placed under other risk warnings, resulting in a significant drop in stock price and market capitalization [1][2]. Group 1: Company Impact - Tianjin Weiming, a key subsidiary, accounted for 60.09% of Weiming Pharmaceutical's revenue and 9.8% of its net profit in 2024, indicating its critical role in the company's financial performance [2]. - The suspension of Tianjin Weiming's production is expected to have a substantial impact on Weiming Pharmaceutical's operations, as the subsidiary's previous issues with product quality have already affected sales and revenue [2][4]. - The company reported a revenue decline of 57.84% in Q1 2025, with a net loss of 36.85 million yuan, reflecting ongoing financial struggles exacerbated by the suspension [4]. Group 2: Regulatory and Market Context - The Tianjin Municipal Drug Administration found that Tianjin Weiming's production did not comply with the Good Manufacturing Practice (GMP) standards, leading to the suspension of its production and sales [1][2]. - Prior to the suspension, Tianjin Weiming faced scrutiny when a batch of its interferon α2b spray was flagged for not meeting biological activity standards, resulting in multiple regions halting purchases [2]. - In December 2023, Tianjin Weiming won a bid for the exclusive supply of interferon α2b spray at a price of 33.58 yuan for a specific volume, but this was later revoked in April 2025, further impacting the company's market position [3].

New Stock Listings - Yitang Co., Ltd. (688729) listed at an issue price of 8.45 on July 8, 2025[1] - Jichuan Pharmaceutical (600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (603389) has a tender offer period from June 10 to July 9, 2025[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 8 trading days remaining until the last trading day[1] - Hengli Tui (000622) has 5 trading days remaining until the last trading day[1] - Tui Shi Jiu You (600462) has 4 trading days remaining until the last trading day[1] Market Volatility - North China Long Dragon (301357) reported severe abnormal fluctuations[1] - Multiple stocks including ST Zhengping (603843) and Hunan Tianyan (600698) have reported abnormal fluctuations[3]

New Stock Issuance - Huadian New Energy (证券代码: 730930) issued shares at a price of 3.18 on July 7, 2025[1] - Jichuan Pharmaceutical (证券代码: 600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (证券代码: 603389) has a tender offer period from June 10 to July 9, 2025[1] Trading Alerts - The last trading day for TSM Jinguang (证券代码: 600190) is in 9 trading days[1] - The last trading day for TSM Jinyou (证券代码: 600462) is in 5 trading days[1] - The last trading day for TSM Gongzhi (证券代码: 000584) is in 3 trading days[1] Abnormal Fluctuations - Northern Long (证券代码: 301357) is experiencing severe abnormal fluctuations[1] - ST Dongjing (证券代码: 002199) reported abnormal fluctuations[3] - ST Yunchuang (证券代码: 835305) reported abnormal fluctuations on July 4, 2025[3]

Group 1 - The core viewpoint of the article emphasizes maintaining three strategic approaches during the mid-year reporting season, focusing on industries with strong trends, performance and valuation alignment, and thematic investment opportunities [13] Group 2 - The first strategy highlights industries with strong industrial trend characteristics, particularly focusing on AI and innovative pharmaceuticals [13] - The second strategy targets industries driven by performance and valuation alignment, with attention on the North American computing chain within communications and electronics, as well as non-ferrous metals and gaming sectors [13] - The third strategy involves sectors with thematic and positional speculation, particularly in military and new energy related to anti-involution [13] - Overall, the rotation of non-ferrous metals, AI hardware, innovative pharmaceuticals, gaming, and military sectors is expected to be the main theme during the mid-year reporting season [13]

Group 1 - Lin Yanglin, the chairman of Xinlicheng, has been placed under detention and is under investigation, which may impact investor confidence despite the company stating the matter is unrelated to its operations [1] - Weiming Pharmaceutical's stock will be suspended for one day due to its trial progress not meeting expectations and its subsidiary's inability to resume normal operations within three months, affecting performance expectations [2] - Tengsheng Bo Pharmaceutical has signed a licensing agreement with Health Yuan Group for the exclusive rights to research, develop, and commercialize BRII-693 in China, providing cash flow and enhancing market expectations [3] Group 2 - China Resources Double Crane announced a cash dividend of 3.71 yuan per 10 shares despite a decline in revenue and net profit, indicating strong cash flow and commitment to shareholders [4] - InnoTech's subsidiary has obtained long-term product certification for a flu detection kit, which is expected to enhance market competitiveness and potentially increase revenue [5]